{"id":238822,"date":"2026-06-12T11:07:03","date_gmt":"2026-06-12T16:07:03","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/06\/making-car-t-cells-safer"},"modified":"2026-06-12T11:07:03","modified_gmt":"2026-06-12T16:07:03","slug":"making-car-t-cells-safer","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/06\/making-car-t-cells-safer","title":{"rendered":"Making CAR T Cells Safer"},"content":{"rendered":"

<\/a><\/p>\n

Research from CCR scientists points toward a strategy for making chimeric antigen receptor (CAR) T-cell therapy, the cell-based immunotherapy that has revolutionized the treatment of some blood cancers, safer and more effective for treating solid tumors.<\/p>\n

The study, led by Gr\u00e9goire Altan-Bonnet, Ph.D.<\/a>, Deputy Chief of the Laboratory of Integrative Cancer Immunology<\/a>, Naomi Taylor, M.D., Ph.D.<\/a>, Senior Investigator in the Pediatric Oncology Branch<\/a>, and Paul Fran\u00e7ois, Ph.D., at the University of Montr\u00e9al, shows how adding certain receptors to CAR T cells can prevent the cells from attacking healthy tissue while simultaneously enhancing their activity against cancer cells. The findings appeared April 10, 2025, in Cell<\/em><\/a>.<\/p>\n

CAR T-cell therapy reprograms patients\u2019 immune cells to be effective cancer killers using genetically engineered chimeric antigen receptors (CARs) that are added to their T cells. CARs are designed to recognize molecules on the surface of cancer cells called antigens, which can usually be found on some healthy cells, too. This leads to manageable side effects for patients with blood cancer, but when CAR T cells designed to target solid tumors attack healthy tissue, the effects can be severe.<\/p>\n","protected":false},"excerpt":{"rendered":"

Research from CCR scientists points toward a strategy for making chimeric antigen receptor (CAR) T-cell therapy, the cell-based immunotherapy that has revolutionized the treatment of some blood cancers, safer and more effective for treating solid tumors. The study, led by Gr\u00e9goire Altan-Bonnet, Ph.D., Deputy Chief of the Laboratory of Integrative Cancer Immunology, Naomi Taylor, M.D., [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,412],"tags":[],"class_list":["post-238822","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-genetics"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/238822","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=238822"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/238822\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=238822"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=238822"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=238822"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}